Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Diabetes and Endocrinology
  • Diabetes and Endocrinology News
  • Research Highlights...

Research Highlights Expanded Clinical Uses of SGLT2 Inhibitors

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2025-01-06T08:30:10+05:30  |  Updated On 6 Jan 2025 12:30 PM IST
SGLT2i Versus DPP-4i as an Add-On Therapy and the Risk of PAD-Related Surgical Events
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

USA: A recent editorial published in the Journal of Cardiothoracic and Vascular Anesthesia highlights the growing clinical applications of sodium-glucose cotransporter-2 (SGLT2) inhibitors.

The first sodium-glucose cotransporter-2 (SGLT2) inhibitor, canagliflozin, received approval in 2013. Since then, several others, including dapagliflozin, ertugliflozin, and empagliflozin, have followed suit. These medications have demonstrated benefits for various conditions, such as type 2 diabetes, hypertension, heart failure, pulmonary diseases, and renal failure. Notably, trials like EMMY and DAPA-MI indicated potential advantages for SGLT2 inhibitors in patients post-acute myocardial infarction (AMI), however, their impacts on critical outcomes like heart failure and mortality remained unclear.

To further investigate, the EMPACT-MI trial was conducted as an international, double-blind, randomized, placebo-controlled study involving 6,522 patients hospitalized for AMI. Participants were randomized to receive either empagliflozin (10 mg/day) or placebo in addition to standard care. The primary endpoint assessed was a composite of hospitalization for heart failure or death from any cause over a median follow-up of 17.9 months. The trial included patients who had experienced AMI within the previous 14 days and either showed a left ventricular ejection fraction (LVEF) of less than 45% or exhibited signs of congestion.

Results showed that 8.2% of patients receiving empagliflozin experienced the primary endpoint compared to 9.1% in the placebo group, which was not statistically significant. Secondary endpoints similarly showed no meaningful differences between the two groups. The authors concluded that empagliflozin did not significantly reduce the risk of hospitalization for heart failure or death compared to placebo in the studied cohort.

While the trial's design was robust, the researchers note that several factors could have influenced the findings. Notably, funding was provided by the company marketing empagliflozin, and the initial sample size was increased to ensure sufficient power. Additionally, many patients had undergone medical optimization before randomization, likely impacting the event rates.

SGLT2 inhibitors target SGLT2 proteins in the kidneys to reduce glucose reabsorption, promoting glycosuria and slowing renal function decline. Their efficacy in improving cardiovascular outcomes has been well-documented in various trials, showing decreasing risks of cardiovascular death and heart failure hospitalization among patients, particularly those with type 2 diabetes.

Despite the negative findings of the EMPACT-MI trial, previous studies have consistently shown cardiovascular benefits associated with SGLT2 inhibitors. This prompted the FDA to expand dapagliflozin’s approval for patients with reduced and preserved ejection fraction heart failure in 2023. The question arises as to why these drugs, effective in other populations, did not demonstrate benefits in the AMI cohort. Differences in clinical management and the timing of treatment interventions may play a role, as patients experiencing AMI often receive rapid therapeutic interventions that could overshadow the potential benefits of SGLT2 inhibitors.

Long-term use of SGLT2 inhibitors has been linked to various positive cardiovascular outcomes, including decreased rates of hospitalization for heart failure and major adverse cardiac events. However, administering these drugs post-AMI may not capitalize on their protective effects, as many patients would have already experienced myocardial injury.

Additionally, the EMPACT-MI trial’s lack of granularity regarding heart failure severity and myocardial injury limits its findings. Therefore, the need arises for future studies to explore these parameters more thoroughly to understand better the potential benefits of SGLT2 inhibitors in this patient population.

"While the EMPACT-MI trial did not support the initiation of SGLT2 inhibitors post-AMI for reducing hospitalization or mortality risks, existing evidence highlights their cardiovascular advantages in broader patient groups. As such, SGLT2 inhibitors will continue to play a crucial role in managing patients at increased risk for cardiovascular complications," Richa Dhawan, Department of Anesthesia and Critical Care, the University of Chicago Medical Center, Chicago, and colleagues concluded.

Reference: https://www.jcvaonline.com/article/S1053-0770(24)00431-2/fulltext

Journal of Cardiothoracic and Vascular AnesthesiaSGLT2 inhibitorscanagliflozindapagliflozinertugliflozinempagliflozinEMPACT-MI trial
Source : Journal of Cardiothoracic and Vascular Anesthesia
Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Featured image representing medico legal

    What's the Role of Expert Opinion in Medical Negligence?

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    Darbapoetin Alfa In Chemotherapy Induced Anaemia: Check out 5 takeaways from recent study

    Darbapoetin Alfa In Chemotherapy Induced Anaemia: Check out 5 takeaways from recent study

    Biosimilar Denosumab of Alkem (Denuril) shows Comparable Efficacy in Treating Postmenopausal Osteoporosis in Indian Women

    Biosimilar Denosumab of Alkem (Denuril) shows Comparable Efficacy in Treating Postmenopausal...

    View All

    Journal Club Today

    Medical Journalism: Need of the Hour - Ft: Dr Prem Aggarwal (Chairman, Medical Dialogues), Dr Nandita Mohan (Head, MDTV Division, Medical Dialogues)

    Medical Journalism: Need of the Hour - Ft: Dr Prem Aggarwal (Chairman, Medical Dialogues), Dr...

    View All

    Health News Today

    Health Bulletin 08/ May/ 2025

    Health Bulletin 08/ May/ 2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok